Trial · NCT02327416
A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)
NCT02327416, Phase 3, Unknown, Tongji Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study). Trials, record NCT02327416. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02327416
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)
- NCT number
- NCT02327416
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 300 participants, estimated
- Lead sponsor
- Tongji Hospital
- Conditions
- Hepatitis B, Chronic
- Interventions
- Y peginterferon alfa-2b, Granulocyte-macrophage colony stimulating factor, Entecavir and or adefovir dipivoxil
- First posted
- 2014-12-30
- Last updated
- 2016-08-15
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of HBsAg loss at week 96 | week 96 | Change from baseline in Percentage of HBsAg loss at week 96 |
| Secondary | Change from baseline in HBsAg quantification and HBsAg decline at week 96 | week 96 | HBsAg quantification and HBsAg decline from baseline are measured. |
| Secondary | Change from baseline in HBsAg seroconversion at week 96 | week 96 | HBsAg seroconversion from baseline is measured. |
| Other | Percentage of HBeAg loss or HBeAg seroconversion at week 96 for HBeAg positive patients | week 96 | Percentage of HBeAg loss or HBeAg seroconversion are measured at week 96 for patients with HBeAg positive at baseline |
| Other | Percentage of HBV DNA normalization and ALT normalization at week 96 | week 96 | Percentage of HBV DNA normalization and ALT normalization at week 96 are measured. |
| Other | Percentage of sustained virology response at week 120 | week 120 | Sustained virology response is measure at follow up week 24 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02327416
GET https://conductscience.org/api/trials/v1/NCT02327416/registered